During the last session, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s traded shares were 0.74 million, with the beta value of the company hitting 1.51. At the end of the trading day, the stock’s price was $16.46, reflecting an intraday gain of 1.11% or $0.18. The 52-week high for the CNTA share is $18.97, that puts it down -15.25 from that peak though still a striking 55.16% gain since the share price plummeted to a 52-week low of $7.38. The company’s market capitalization is $2.17B, and the average intraday trading volume over the past 10 days was 0.49 million shares, and the average trade volume was 564.45K shares over the past three months.
Centessa Pharmaceuticals plc ADR (CNTA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CNTA has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.35.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Centessa Pharmaceuticals plc ADR (CNTA) registered a 1.11% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.11% in intraday trading to $16.46, hitting a weekly high. The stock’s 5-day price performance is 10.69%, and it has moved by -4.08% in 30 days. Based on these gigs, the overall price performance for the year is 104.73%. The short interest in Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is 3.63 million shares and it means that shorts have 6.18 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 28.43% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $28 respectively. As a result, CNTA is trading at a discount of -70.11% off the target high and -15.43% off the low.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
Statistics show that Centessa Pharmaceuticals plc ADR has underperformed its competitors in share price, compared to the industry in which it operates. Centessa Pharmaceuticals plc ADR (CNTA) shares have gone up 60.74% during the last six months, with a year-to-date growth rate less than the industry average at -1.91% against 16.80. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
While earnings are projected to return 2.97% in 2025, the next five years will return -3.20% per annum.
CNTA Dividends
Centessa Pharmaceuticals plc ADR is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
Centessa Pharmaceuticals plc ADR insiders own 1.24% of total outstanding shares while institutional holders control 92.61%, with the float percentage being 93.77%. MEDICXI VENTURES MANAGEMENT (JERSEY) LTD is the largest shareholder of the company, while 129.0 institutions own stock in it. As of 2024-06-30, the company held over 19.96 million shares (or 19.9856% of all shares), a total value of $180.27 million in shares.
The next largest institutional holding, with 9.68 million shares, is of GENERAL ATLANTIC, L.P.’s that is approximately 9.6927% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $87.43 million.
Also, the Mutual Funds coming in first place with the largest holdings of Centessa Pharmaceuticals plc ADR (CNTA) shares are Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund . Data provided on Nov 30, 2024 indicates that Fidelity Select Portfolios – Biotechnology owns about 2.98 shares. This amounts to just over 2.26 percent of the company’s overall shares, with a $48.99 million market value. The same data shows that the other fund manager holds slightly less at 2.95, or about 2.24% of the stock, which is worth about $48.5 million.
